NasdaqGM:IOVABiotechs
Iovance Biotherapeutics (IOVA) Trailing Loss Improvement Tests Bearish Profitability Narratives
Iovance Biotherapeutics (IOVA) opened Q1 2026 with revenue of US$71.4 million and a basic EPS loss of US$0.19, alongside net income excluding extra items at a loss of US$79.0 million. Over recent quarters, the company has seen revenue move from US$49.3 million in Q1 2025 to US$71.4 million in Q1 2026. Quarterly basic EPS losses ranged between US$0.18 and US$0.36 across that period, illustrating that top line scale is increasing while spending remains high and margins stay under pressure.
See...